Technical Analysis for ZVRA - Zevra Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week High | Strength | 0.00% | |
20 DMA Support | Bullish | 4.30% | |
MACD Bearish Signal Line Cross | Bearish | 4.06% | |
20 DMA Support | Bullish | 4.06% | |
20 DMA Support | Bullish | -0.66% | |
New 52 Week Closing High | Bullish | -0.66% | |
Pocket Pivot | Bullish Swing Setup | -0.66% | |
New 52 Week High | Strength | -0.66% | |
Upper Bollinger Band Touch | Strength | -0.66% | |
Gapped Down | Weakness | -0.66% |
Alert | Time |
---|---|
Down 2 % | about 16 hours ago |
Upper Bollinger Band Resistance | about 20 hours ago |
New 52 Week High | about 20 hours ago |
Up 3% | about 20 hours ago |
60 Minute Opening Range Breakout | about 21 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/12/2024
Zevra Therapeutics, Inc. Description
Zevra Therapeutics, Inc., a rare disease therapeutics company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. Zevra Therapeutics, Inc. has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Disease Drugs Rare Diseases FDA Psychoactive Drugs Euphoriants Attention Deficit Hyperactivity Disorder Narcolepsy Amphetamine Methylphenidate Hydrocodone Idiopathic Hypersomnia Stimulants
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 9.27 |
52 Week Low | 4.2 |
Average Volume | 934,821 |
200-Day Moving Average | 6.32 |
50-Day Moving Average | 8.12 |
20-Day Moving Average | 8.56 |
10-Day Moving Average | 8.82 |
Average True Range | 0.52 |
RSI (14) | 59.18 |
ADX | 19.96 |
+DI | 22.09 |
-DI | 13.57 |
Chandelier Exit (Long, 3 ATRs) | 7.70 |
Chandelier Exit (Short, 3 ATRs) | 9.24 |
Upper Bollinger Bands | 9.29 |
Lower Bollinger Band | 7.82 |
Percent B (%b) | 0.78 |
BandWidth | 17.20 |
MACD Line | 0.23 |
MACD Signal Line | 0.23 |
MACD Histogram | -0.0032 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 9.81 | ||||
Resistance 3 (R3) | 9.82 | 9.54 | 9.67 | ||
Resistance 2 (R2) | 9.54 | 9.33 | 9.54 | 9.62 | |
Resistance 1 (R1) | 9.26 | 9.20 | 9.12 | 9.25 | 9.58 |
Pivot Point | 8.98 | 8.98 | 8.92 | 8.98 | 8.98 |
Support 1 (S1) | 8.70 | 8.77 | 8.56 | 8.69 | 8.36 |
Support 2 (S2) | 8.42 | 8.64 | 8.42 | 8.32 | |
Support 3 (S3) | 8.14 | 8.42 | 8.27 | ||
Support 4 (S4) | 8.13 |